## **Core Concept**
Macular toxicity refers to damage to the macula, a part of the retina responsible for central vision, fine detail, and color perception. Intravitreal administration of drugs involves injecting medications directly into the vitreous humor of the eye, which can be effective for treating various ocular conditions but also carries risks of toxicity.

## **Why the Correct Answer is Right**
The correct answer involves identifying drugs known to cause macular toxicity when administered intravitreally. Among the options provided, **Sirolimus (also known as rapamycin)** and other mTOR inhibitors can cause macular toxicity. However, without specific options detailed, we focus on the concept that certain drugs, especially those not typically used intravitreally or at high doses, can cause such toxicity.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Without specifics, we can't directly address why A is incorrect, but generally, drugs not associated with macular toxicity or not commonly administered intravitreally would be wrong.
- **Option B:** Similarly, B would be incorrect if it doesn't align with known macular toxicities from intravitreal drugs.
- **Option C:** This would be incorrect if it represents a drug not commonly linked with macular toxicity via intravitreal administration.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **intravitreal injections** of certain drugs, like **anti-VEGF agents** (e.g., bevacizumab, ranibizumab), are commonly used for conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME), but careful monitoring for signs of macular toxicity or other adverse effects is crucial.

## **Correct Answer:** .